Back to News
Market Impact: 0.2
Pyxis Oncology, Inc. Reports Third Quarter 2026 Financial Results
Source: Nasdaq
Healthcare & BiotechCorporate EarningsCompany Fundamentals
Pyxis Oncology reported a net loss of $20.0 million, or $0.24 per common share, for the quarter ended September 30, 2026, and highlighted development progress for micvotabart pelidotin (MICVO). The article text is truncated before the prior-period comparison is stated, so the change in results cannot be assessed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.00
More News
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FTSE 100 today: Stocks slump as global tech rout deepens